Shalby Ltd Reports FY26 Revenue Growth, MedTech Business Turns Profitable

Shalby Limited's consolidated total income for FY 2025-26 reached Rs 1,168 crore, an increase from Rs 1,115 crore in the previous fiscal year. Consolidated operating profit rose to Rs 170 crore. The company's reported profit after tax saw a significant jump, primarily due to a one-time tax benefit.

Reader Takeaway: MedTech turnaround is positive, but hospital occupancy pressure remains a key concern.

What just happened

Shalby Limited announced its financial results for the fiscal year 2025-26. Total income grew by 4.7% to Rs 1,168 crore. The company's MedTech segment achieved profitability, reporting an operating profit of Rs 7 crore after being in a loss the prior year. However, the core hospital operations faced margin pressure with occupancy at 46%.

Why this matters

The results indicate a mixed performance. The profitable turnaround of the MedTech business is a significant positive development. However, the continued pressure on hospital occupancy and margins highlights ongoing challenges in the company's primary revenue-generating segment. The ICRA rating revision to 'Negative' also signals increased financial scrutiny.

The backstory

Shalby Limited is a healthcare company with operations in hospital services and medical technology manufacturing. The company has been focused on expanding its MedTech business, which includes orthopaedic implants and surgical instruments. In the previous fiscal year (FY25), the hospital segment was the primary profit driver, while MedTech incurred losses.

What changes now

The successful transition of the MedTech business to profitability is a key strategic achievement. The appointment of Mr. Shanay Vikram Shah as a Whole-Time Director, subject to shareholder approval, aims to strengthen the board. The company is also pursuing an asset-light expansion strategy.

Risks to watch

The primary risks include the sustained low occupancy rates in the hospital segment and potential difficulties in improving margins. The 'Negative' outlook from ICRA suggests potential challenges in debt servicing or future funding, which could impact expansion plans.

Peer comparison

While specific peer data for FY26 is not provided, the healthcare sector generally faces competition from both large hospital chains and specialized medical device manufacturers. Shalby's dual focus on hospitals and MedTech places it in a unique competitive landscape.

Context metrics (time-bound)

• FY 2025-26 Total Income: Rs 1,168 crore (vs Rs 1,115 crore in FY 2024-25)
• FY 2025-26 Operating Profit: Rs 170 crore
• MedTech Segment FY 2025-26 Operating Profit: Rs 7 crore (vs loss of Rs 19 crore in FY25)
• Hospital Operations Occupancy: 46% (vs 47% in FY25)

What to track next

Investors will be keen to monitor improvements in hospital occupancy rates, the continued growth and profitability of the MedTech segment, and management's strategies to address the revised credit outlook. The outcome of the upcoming AGM regarding the board appointment will also be important.